Renagel

Renagel is a brand name of sevelamer, approved by the FDA in the following formulation(s):

RENAGEL (sevelamer hydrochloride - tablet; oral)

• 
  Manufacturer: GENZYME
  
  Approval date: July 12, 2000
  
  Strength(s): 400MG, 800MG ^[RLD]

Has a generic version of Renagel been approved?

No. There is currently no therapeutically equivalent version of Renagel available.

Note: Fraudulent online pharmacies may attempt to sell an illegal generic version of Renagel. These medications may be counterfeit and potentially unsafe. If you purchase medications online, be sure you are buying from a reputable and valid online pharmacy. Ask your health care provider for advice if you are unsure about the online purchase of any medication.

See also: About generic drugs.

Related Patents

Patents are granted by the U.S. Patent and Trademark Office at any time during a drug's development and may include a wide range of claims.

• 
  Phosphate-binding polymers for oral administration
  Patent 5,496,545
  Issued: March 5, 1996
  Inventor(s): Holmes-Farley; Stephen R. & Mandeville, III; W. Harry & Whitesides; George M.
  Assignee(s): GelTex Pharmaceuticals, Inc.
  Phosphate-binding polymers are provided for removing phosphate from the gastrointestinal tract. The polymers are orally administered, and are useful for the treatment of hyperphosphatemia.
  
  Patent expiration dates:
  
  
  • August 11, 2013
    
    ✓ 
    Patent use: PHOSPHATE BINDING
  
  



• 
  Phosphate-binding polymers for oral administration
  Patent 5,667,775
  Issued: September 16, 1997
  Inventor(s): Holmes-Farley; Stephen Randall & Mandeville, III; W. Harry & Whitesides; George M.
  Assignee(s): GelTex Pharmaceuticals, Inc.
  Phosphate-binding polymers are provided for removing phosphate from the gastrointestinal tract. The polymers are orally administered, and are useful for the treatment of hyperphosphatemia.
  
  Patent expiration dates:
  
  
  • September 16, 2014
    
    ✓ 
    Patent use: PHOSPHATE BINDING
  
  



• 
  Method of making phosphate-binding polymers for oral administration
  Patent 6,509,013
  Issued: January 21, 2003
  Inventor(s): Stephen Randall; Holmes-Farley & W. Harry; Mandeville, III & George M.; Whitesides
  Assignee(s): GelTex Pharmaceuticals, Inc.
  Phosphate-binding polymers are provided for removing phosphate from the gastrointestinal tract. The polymers are orally administered, and are useful for the treatment of hyperphosphatemia.
  
  Patent expiration dates:
  
  
  • August 11, 2013
    
  
  



• 
  Direct compression polymer tablet core
  Patent 6,733,780
  Issued: May 11, 2004
  Inventor(s): Joseph; Tyler & John S.; Petersen
  Assignee(s): Genzyme Corporation
  The present invention provides a tablet core which comprises at least about 95% by weight of an aliphatic amine polymer. The invention also provides a method of producing a tablet core comprising at least about 95% by weight of an aliphatic amine polymer resin. The method comprises the step of compressing the aliphatic amine polymer to form the tablet core. The tablet core can further include one or more excipients. In this embodiment the method of producing the tablet core comprises the steps of: (1) hydrating the aliphatic amine polymer to the desired moisture level; (2) blending the aliphatic amine polymer with the excipients in amounts such that the polymer comprises at least about 95% by weight of the resulting blend; and (3) compressing the blend to form the tablet core. The present invention further relates to a coated tablet comprising an aliphatic amine polymer core wherein the coating is a water based coating.
  
  Patent expiration dates:
  
  
  • October 18, 2020
    
    ✓ 
    Drug product
  
  



• 
  Phosphate-binding polymers for oral administration
  Patent 7,014,846
  Issued: March 21, 2006
  Inventor(s): Holmes-Farley; Stephen Randall & Manderville, III; W. Harry & Whitesides; George M.
  Assignee(s): Genzyme Corporation
  Phosphate-binding polymers are provided for removing phosphate from the gastrointestinal tract. The polymers are orally administered, and are useful for the treatment of hyperphosphatemia.
  
  Patent expiration dates:
  
  
  • August 11, 2013
    
    ✓ 
    Patent use: PHOSPHATE BINDING
    ✓ 
    Drug product
  
  



• 
  Phosphate-binding polymers for oral administration
  Patent 7,459,151
  Issued: December 2, 2008
  Inventor(s): Holmes-Farley; Stephen Randall & Mandeville, III; W. Harry & Whitesides; George M.
  Assignee(s): Genzyme Corporation
  Phosphate-binding polymers are provided for removing phosphate from the gastrointestinal tract. The polymers are orally administered, and are useful for the treatment of hyperphosphatemia.
  
  Patent expiration dates:
  
  
  • August 11, 2013
    
    ✓ 
    Patent use: PHOSPHATE BINDING
  
  

Related Exclusivities

Exclusivity is exclusive marketing rights granted by the FDA upon approval of a drug and can run concurrently with a patent or not. Exclusivity is a statutory provision and is granted to an NDA applicant if statutory requirements are met.

• Exclusivity expiration dates:
  • October 19, 2010 - INDICATION EXPANDED TO INCLUDE PATIENTS ON PERITONEAL DIALYSIS
  
  

See also...

• Renagel Consumer Information (Drugs.com)
• Renagel Consumer Information (Wolters Kluwer)
• Renagel Consumer Information (Cerner Multum)
• Renagel Advanced Consumer Information (Micromedex)
• Sevelamer Consumer Information (Wolters Kluwer)
• Sevelamer Powder Packets Consumer Information (Wolters Kluwer)
• Sevelamer Consumer Information (Cerner Multum)
• Sevelamer Advanced Consumer Information (Micromedex)
• Sevelamer AHFS DI Monographs (ASHP)